Partner at Kirkland & Ellis LLP
Nicola Dagg is a partner in the IP litigation team in the London office of Kirkland & Ellis International LLP. Ms Dagg’s practice spans four areas:
- strategic life sciences patent and product lifecycle advice;
- patent litigation;
- coordinating global IP enforcement/defence cases; and
- SEP FRAND disputes.
Ms Dagg has extensive experience in pharmaceutical and biologics patent litigation including blockbuster small molecule litigation against generic companies, biologics and biosimilar litigation, antibodies, immunotherapies, genetics, vaccines, diagnostics and gene therapies. She also acts in market-leading SEP essentiality, validity and global FRAND adjudication litigation in the tech sector. Having served as UK and European/global coordinating counsel for numerous strategic IP litigation cases and drawing on more than 24 years of legal, IP, life sciences and tech experience she helps clients solve their most pressing global challenges. She has tried more than 20 cases.
Ms Dagg writes and speaks extensively on IP litigation. She was named Lawyer of the Year 2017 for Life Sciences (Patent Litigation); she is ranked as a leading IP partner in Chambers UK and Legal 500. Ms Dagg has also been selected as one of the 10 “Most Highly Regarded Individuals” in Europe by Who’s Who Legal: Patents 2016 and was named as one of the “Top 50 women lawyers in London” in the 2015 Super Lawyers list. Who’s Who Legal has listed her as an expert in each of patent lawyers, life sciences patent litigation and as a thought leader for life sciences.
Ms Dagg has consistently been recognised as a gold-ranked patent litigator by IAM Patent 1000 and in their 2019 directory they describe her as “fantastic – the driving force in what is one of the great success stories in recent years” and acknowledge her “impressive” team-building and client-handling skills.
Ms Dagg holds an MA in natural sciences from Newnham College, University of Cambridge, and a diploma in IP law and practice from the University of Bristol.